Introduction
The logic is sound on its face. Whatever cannabis does, it is not fentanyl. Nobody dies of a cannabis overdose. If the choice is between injecting an unregulated opioid and smoking a joint, only one of those has a body count.
That reasoning is not stupid, and it is not the same as evidence that this works. Both things are true, and the gap between them is where people get hurt.
First: The Harm Reduction Point Is Real
Let's concede what should be conceded.
If someone moves from injecting an opioid from an unregulated supply — currently contaminated with fentanyl, nitazenes, and veterinary sedatives that naloxone will not reverse — to smoking cannabis, they have reduced their risk of dying this year by an enormous margin.
Telling that person they aren't "really sober" is technically defensible and practically useless. Purity of definition has never kept anybody alive.
So this article is not going to lecture you about whether it counts.
But the Evidence for Substitution Is Thin
Here the picture diverges sharply from the confident version you'll find online.
For alcohol, there is now a randomized controlled trial suggesting cannabis reduces drinking in a laboratory — and even its own authors warned it would be premature and potentially risky to recommend cannabis as a therapeutic substitute.
For opioids, the evidence is considerably weaker.
A national survey of US adults found that people perceive cannabis as having reduced their opioid use — but the prevalence of actually discontinuing opioids was not significantly different between daily or near-daily cannabis users and non-users.1 The researchers noted plainly that self-reported improvement has not been substantiated by studies that objectively monitored both substances, and suggested that commercialization and favourable media coverage may be feeding the perception.
That is an uncomfortable finding. The belief that this works is much better established than the fact.
For stimulants, there is essentially nothing to report.
What the Research Does Support
One thing, and it is narrower than it sounds.
A systematic review of 41 studies of people receiving medication for opioid use disorder concluded that cannabis use appears unlikely to undermine treatment progress.2
Read that carefully. It says cannabis probably won't wreck your buprenorphine or methadone treatment. It does not say cannabis is a substitute for that treatment. Those are entirely different claims, and the first is routinely quoted as though it were the second.
The Treatment You'd Be Declining
This is the crux, and it is why the question matters more here than it does with alcohol.
Opioid use disorder has treatments with strong evidence. Buprenorphine and methadone reduce opioid use and — this is the part that matters — reduce mortality. They are first-line care.
If switching to cannabis means not taking them, the trade being made is not "hard drug for soft drug." It is "the intervention that reduces death, for one that has never been shown to."
That is a substantially worse deal than it appears, and it is being made by a great many people who would take the medication if anyone had told them what it does.
Cannabis Use Disorder Is Not Theoretical
The other thing people underweight.
In one study of patients receiving opioid maintenance therapy, 41% used cannabis — and among those users, 73% met criteria for cannabis dependence. That is roughly thirty percent of the entire sample, dependent on the substance they had adopted as the safer option.
Cannabis use disorder is a recognized clinical condition. It escalates. Modern high-potency products are not the ones in your memory. And there are people for whom high-THC cannabis carries genuine psychiatric risk.
The substitute becoming the problem is not a hypothetical. It is a documented pattern.
The Question Underneath
Worth asking honestly, because it usually decides the outcome.
Is the cannabis doing the same job the other drug was doing? Managing a feeling, filling an evening, providing the reliable off-switch, marking the end of the day?
If so, the machinery is still running. The ritual, the anticipation, the reward — all intact, all pointed at a substance. Which means the return to the original drug becomes a question of circumstance rather than of resolve.
And a second question: has it escalated? In amount, in frequency, in how early it starts? Could you stop for a month, easily, if you decided to?
Two Practical Things
Judgment narrows under intoxication. The person who has been smoking for three hours is not the person who decided, sober, never to touch opioids again. Whatever your view on substitution, intoxication reliably removes the version of you who is holding the line.
And it puts you in the same rooms. The bar has your drink and it also has the person who can get you the other thing. Substances tend to share hours, places, and people, regardless of pharmacology.
What to Actually Do
If opioids were the problem, ask a prescriber about buprenorphine or methadone by name. Ask what the evidence says about mortality. This is the single highest-value conversation available to you, and most people never have it.
If you are going to use cannabis regardless, watch escalation rather than amount, tell someone how much you actually use, and get an assessment if you meet criteria for a substance use disorder.
And do not read this as a verdict on your worth. You found something less likely to kill you. That instinct was sound. It just isn't the treatment, and there is one.
The Bottom Line
Yes, cannabis is far less likely to kill you than fentanyl, and a person who makes that switch has genuinely reduced their risk. But people's perception that cannabis reduces their opioid use is not borne out when both are actually measured, and among opioid-treatment patients who use cannabis, 73% met dependence criteria. Most importantly: buprenorphine and methadone reduce mortality, and switching to weed instead of taking them trades the treatment that saves lives for one that has never been shown to.
Sources
- Perceived but not objective substitution — Substitution of marijuana for opioids in a national survey of US adults. PLOS ONE (2019). View source ↗ (survey found no significant difference in opioid discontinuation between cannabis users and non-users)
- Cannabis unlikely to undermine MOUD - NOT a substitute claim — The relationship between cannabis use and patient outcomes in medication-based treatment of opioid use disorder: A systematic review. View source ↗ (systematic review; 'unlikely to undermine' treatment progress is not the same as being a substitute)